Loading...
Loading...
- Pacific Biosciences of California Inc PACB has agreed to acquire Omniome, a San Diego-based company developing a short-read sequencing platform.
- Under the terms of the agreement, PacBio will acquire Omniome for an upfront payment of $600 million consisting of 9.4 million PacBio shares and $300 million in cash, plus an additional $200 million as milestone payments.
- PacBio has announced private placement of approximately 11.2 million shares at $26.75 per share in connection with the proposed acquisition, for gross proceeds of roughly $300 million.
- PacBio also announced preliminary revenue of approximately $30.5 million for Q2 of 2021, representing about 78% Y/Y growth versus a $29.9M estimate.
- The Company will release full Q2 financial results on August 3.
- Pacific Biosciences and Invitae Corporation NVTA announced an intent to expand their multi-year collaboration to develop a production-scale high-throughput HiFi sequencing platform to include the sequencing technology developed by Omniome.
- Price Action: PACB shares are up 1.03% at $27.51 during the market session on the last check Tuesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in